Effects of NOX1 Inhibition on Real-Time Blood Nitric Oxide
and Hydrogen Peroxide Levels in Acute Hyperglycemia
Ashley E. Mawhinney, Matthew Bertolet, Michael Minni, Robert Barsotti, Lindon Young, Qian Chen
Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine
4170 City Avenue, Philadelphia, PA 19131

Introduction

Methods

Chronic hyperglycemia is a major condition of diabetes and it leads to vascular
complications in diabetic patients. In non-diabetic patients, acute hyperglycemia
also results in decreased wound healing and immune function, increased
myocardial infarction size post myocardial infarction, and mortality. These effects
of hyperglycemia are initiated by vascular endothelial dysfunction which is
characterized by increased levels of reactive oxygen species (ROS) and decreased
levels of endothelial-derived nitric oxide (NO). Endothelial NO synthase (eNOS)
produces NO and is responsible for maintaining an anti-inflammatory surface to
facilitate blood flow. NADPH oxidases are a principle source of superoxide (SO)
during inflammation [1]. SO can directly quench NO by forming peroxynitrite
which induces eNOS uncoupling and additional ROS release (see figure 1).

Male Sprague-Dawley rats (275-325g; Charles River, Springfield, MA) were
anesthetized and subsequently infused with saline, 30% glucose, or 30% glucose
with 20 µg/Kg or 100 µg/Kg ML171 (approximately 1 or 5 µM in blood) via the
cannulation of jugular vein. Hyperglycemic conditions (≥200 mg/dL) were
induced, maintained, and monitored as previously described [4]. Mean arterial
blood pressure (MABP) was monitored through catheterization of the carotid
artery. Blood NO and H2O2 levels were measured in real time by NO or H2O2
microsensors as previously described (see figure 3) [4]. All data in the figures are
presented as means ± S.E.M. The data were analyzed by ANOVA using the
Student- Newman- Keuls post hoc test, p<0.05 were considered to be statistically
significant.

Figure 1. The possible roles of NADPH
oxidase and eNOS uncoupling in
hyperglycemia-induced vascular
endothelial dysfunction.

Figure 3. Nitric oxide and hydrogen peroxide
sensors in the femoral veins.

Results

Figure 6. Comparison of blood NO levels relative to saline among 30% D-glucose, 30% D-glucose with 1μM
ML171, and 30% D-glucose with 5μM ML171(*p<0.05, **p<0.01 vs Glucose). Hyperglycemia significantly
reduced blood NO levels (101.41±10.91 nM, n=8). ML171 (1 and 5 μM) attenuated the hyperglycemia induced
decrease in blood NO levels and increased blood NO levels by 68.48±12.67 nM (P<0.01, n=5) and 85.95±8.13 nM
(P<0.01, n=5) respectively at 180 min.. Saline showed no change throughout the experiment.

SO is rapidly converted to H2O2, which can be measured in blood due to its
relatively longer half-life (i.e., minutes vs seconds). There are 7 isoforms of
NADPH oxidase (NOX) in mammals. Of these isoforms, NOX1 and NOX2 are
mainly expressed in vascular endothelial cells and smooth muscle cells [2].
Previously, we have shown that gp91ds-tat, a NOX2 inhibitor, partially reduced
blood H2O2 levels induced by hyperglycemic conditions [1]. However, the role of
NOX1 in hyperglycemia induced oxidative stress and vascular endothelial
dysfunction is still unclear. In this study, 2-acetylphenothiazine (ML171), a
specific inhibitor for NOX1, was used to determine the role of NOX1 in
hyperglycemia-induced vascular endothelial dysfunction by measuring blood NO
and H2O2 levels in real-time (see figure 2) [3].
ML171

Figure 4. Blood glucose changes throughout 180 minute experiment with 30% D-glucose. Blood
glucose levels were maintained at ~200 mg/dL in all study groups except for saline.

Figure 7. Comparison of blood H2O2 levels relative to saline among 30% D-glucose, 30% D-glucose with 1μM
ML171, and 30% D-glucose with 5μM ML171(*p<0.05, **p<0.01 vs Glucose). Hyperglycemia significantly
increased blood H2O2 levels by 3 ± 0.42 μM (n =9). ML171 (1 and 5 μM) significantly decreased blood H2O2 levels
by 1.86 ± 0.61 μM (n=8) and 4.85 ± 1.02 μM (n=5) respectively at 180 min. Saline showed no change throughout the
experiment.

Conclusions
Our results indicate that NOX1 activation is a key mechanism contributing to acute
hyperglycemia-induced oxidative stress and NO reduction in vascular tissue.
Furthermore, inhibition of NOX1 may mitigate the deleterious effects of acute
hyperglycemia. The outcomes from this study suggest that ML171 may be a
therapeutic tool to attenuate vascular dysfunction associated with diabetic patients.

Figure 2. Structure of NADPH Oxidase Isoform 1 (NOX1) and its selective inhibitor, ML171.

Hypothesis
We hypothesized that acute hyperglycemia (200 mg/dL) would increase blood
H2O2 levels and decrease blood NO levels compared to saline control. By inhibiting
NOX1 using ML171(2-acetylphenothiazine, MW=241.31 g/mol, Tocris
Bioscience), acute hyperglycemia-induced vascular dysfunction would be
attenuated. This will be noted by decreased blood H2O2 levels and increased blood
NO levels compared to acute hyperglycemia control.
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